Silence Therapeutics plc Deferred Tax Assets, Unrealized Losses on Trading Securities
Silence Therapeutics plc (SLNCF) had Deferred Tax Assets, Unrealized Losses on Trading Securities of $73.53 million as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities · last filed 2026-03-05
- 2025-12-31: Deferred Tax Assets, Unrealized Losses on Trading Securities $73.53M.
- 2024-12-31: Deferred Tax Assets, Unrealized Losses on Trading Securities $55.32M.
- 2023-12-31: Deferred Tax Assets, Unrealized Losses on Trading Securities $57.56M.
| Period end | Deferred Tax Assets, Unrealized Losses on Trading Securities |
|---|---|
| 2025-12-31 | $73.53M 10-K · filed 2026-03-05 |
| 2024-12-31 | $55.32M 10-K · filed 2026-03-05 |
| 2023-12-31 | $57.56M 10-K · filed 2025-02-27 |